S&P 500   4,278.86 (+0.12%)
DOW   33,523.29 (-0.12%)
QQQ   354.63 (-0.08%)
AAPL   179.33 (-0.14%)
MSFT   333.62 (-0.69%)
META   272.06 (+0.25%)
GOOGL   127.70 (+1.34%)
AMZN   126.50 (+0.96%)
TSLA   220.24 (+1.21%)
NVDA   385.35 (-1.62%)
NIO   7.83 (+2.09%)
BABA   86.77 (+2.81%)
AMD   122.96 (+4.27%)
T   15.62 (+1.49%)
F   12.89 (+2.38%)
MU   67.50 (-0.40%)
CGC   0.73 (-6.62%)
GE   105.28 (+1.13%)
DIS   92.17 (+1.29%)
AMC   4.65 (+0.43%)
PFE   38.43 (-0.57%)
PYPL   64.84 (+0.51%)
NFLX   398.76 (-1.18%)
S&P 500   4,278.86 (+0.12%)
DOW   33,523.29 (-0.12%)
QQQ   354.63 (-0.08%)
AAPL   179.33 (-0.14%)
MSFT   333.62 (-0.69%)
META   272.06 (+0.25%)
GOOGL   127.70 (+1.34%)
AMZN   126.50 (+0.96%)
TSLA   220.24 (+1.21%)
NVDA   385.35 (-1.62%)
NIO   7.83 (+2.09%)
BABA   86.77 (+2.81%)
AMD   122.96 (+4.27%)
T   15.62 (+1.49%)
F   12.89 (+2.38%)
MU   67.50 (-0.40%)
CGC   0.73 (-6.62%)
GE   105.28 (+1.13%)
DIS   92.17 (+1.29%)
AMC   4.65 (+0.43%)
PFE   38.43 (-0.57%)
PYPL   64.84 (+0.51%)
NFLX   398.76 (-1.18%)
S&P 500   4,278.86 (+0.12%)
DOW   33,523.29 (-0.12%)
QQQ   354.63 (-0.08%)
AAPL   179.33 (-0.14%)
MSFT   333.62 (-0.69%)
META   272.06 (+0.25%)
GOOGL   127.70 (+1.34%)
AMZN   126.50 (+0.96%)
TSLA   220.24 (+1.21%)
NVDA   385.35 (-1.62%)
NIO   7.83 (+2.09%)
BABA   86.77 (+2.81%)
AMD   122.96 (+4.27%)
T   15.62 (+1.49%)
F   12.89 (+2.38%)
MU   67.50 (-0.40%)
CGC   0.73 (-6.62%)
GE   105.28 (+1.13%)
DIS   92.17 (+1.29%)
AMC   4.65 (+0.43%)
PFE   38.43 (-0.57%)
PYPL   64.84 (+0.51%)
NFLX   398.76 (-1.18%)
S&P 500   4,278.86 (+0.12%)
DOW   33,523.29 (-0.12%)
QQQ   354.63 (-0.08%)
AAPL   179.33 (-0.14%)
MSFT   333.62 (-0.69%)
META   272.06 (+0.25%)
GOOGL   127.70 (+1.34%)
AMZN   126.50 (+0.96%)
TSLA   220.24 (+1.21%)
NVDA   385.35 (-1.62%)
NIO   7.83 (+2.09%)
BABA   86.77 (+2.81%)
AMD   122.96 (+4.27%)
T   15.62 (+1.49%)
F   12.89 (+2.38%)
MU   67.50 (-0.40%)
CGC   0.73 (-6.62%)
GE   105.28 (+1.13%)
DIS   92.17 (+1.29%)
AMC   4.65 (+0.43%)
PFE   38.43 (-0.57%)
PYPL   64.84 (+0.51%)
NFLX   398.76 (-1.18%)
NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Forecast, Price & News

$1.50
-0.03 (-1.96%)
(As of 02:36 PM ET)
Compare
Today's Range
$1.31
$1.57
50-Day Range
$1.53
$2.16
52-Week Range
$1.31
$13.50
Volume
338,098 shs
Average Volume
184,333 shs
Market Capitalization
$2.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BVXV stock logo

About BiondVax Pharmaceuticals (NASDAQ:BVXV) Stock

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
BVXV: Developing anti-IL-17 NanoAb
Is There Still Time to Get In On the Lithium Boom?
"Lithium demand from the electric vehicle (EV) industry is growing at twice the rate of lithium production. By 2030, experts predict that 26 million EVs will be on U.S. roads, up from around 600,000 today. That's why new government incentives have been put in place to support more urgently-needed "Made in America" lithium.
BiondVax to Present at BIO-Europe Spring
BiondVax Presenting at BIO CEO & Investor Conference
See More Headlines

BVXV Price History

BVXV Company Calendar

Last Earnings
4/17/2023
Today
6/06/2023
Next Earnings (Estimated)
8/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BVXV
Employees
15
Year Founded
N/A

Profitability

Net Income
$-5,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.94) per share

Miscellaneous

Free Float
1,755,000
Market Cap
$2.81 million
Optionable
Not Optionable
Beta
2.47

Key Executives

  • Amir Reichman
    Chief Executive Officer & Director
  • Elad Mark
    Chief Operating Officer
  • Uri Ben-Or
    Chief Financial Officer
  • Tamar Ben-Yedidia
    Chief Science Officer
  • Dalit Weinstein Fischer
    Head-Technical, Research & Development













BVXV Stock - Frequently Asked Questions

How have BVXV shares performed in 2023?

BiondVax Pharmaceuticals' stock was trading at $2.96 at the beginning of the year. Since then, BVXV stock has decreased by 49.3% and is now trading at $1.50.
View the best growth stocks for 2023 here
.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 18,000 shares, an increase of 20.8% from the April 30th total of 14,900 shares. Based on an average daily trading volume, of 27,000 shares, the days-to-cover ratio is currently 0.7 days.
View BiondVax Pharmaceuticals' Short Interest
.

When is BiondVax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023.
View our BVXV earnings forecast
.

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) released its quarterly earnings results on Monday, April, 17th. The company reported ($0.30) earnings per share for the quarter.

When did BiondVax Pharmaceuticals' stock split?

BiondVax Pharmaceuticals's stock reverse split on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

Who are BiondVax Pharmaceuticals' major shareholders?

BiondVax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (17.45%).

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $1.50.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $2.81 million. The company earns $-5,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.

This page (NASDAQ:BVXV) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -